InvestorsHub Logo
Followers 88
Posts 1770
Boards Moderated 0
Alias Born 09/03/2009

Re: Mikesc post# 30463

Thursday, 11/05/2015 10:38:43 AM

Thursday, November 05, 2015 10:38:43 AM

Post# of 461733
Interesting - In the abstract you have linked to that is combined with all the others, there is more 'color' to the data:

In the secondary outcome endpoints preliminary
analysis of data from subjects to date shows an average improvement
of the MMSE score at week 12 in PART B (week 17 from baseline).
A significant majority of all patients tested so far improved their
respective MMSE score.
The average EEG/ERP (P300 amplitude)
signal also improved and also the average Cogstate test improved
across the test batteries.
Conclusions:
Data collected so far indicate
that ANAVEX 2-73 is safe and well tolerated. Interim results also
show improved cognitive performance
after drug administration in
subjects with mild-to-moderate AD.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News